Uroplasty, Inc.

Shareholder Corporation Litigation

Rigrodsky & Long, P.A. Announces Investigation Of Uroplasty, Inc. (NASDAQ CM: UPI) Buyout

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Uroplasty, Inc. (“Uroplasty” or the “Company”) (NASDAQ CM: UPI) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Vision-Sciences, Inc. (“Vision-Sciences”) (NASDAQ CM: VSCI).

Under the terms of the agreement, shareholders of Uroplasty will receive 3.6331 shares of Vision-Sciences common stock for each share of Uroplasty common stock.  Based on Vision-Sciences’ closing stock price on December 19, 2014, Uroplasty shareholders would have received consideration valued at approximately $3.67 per share.

The investigation concerns whether Uroplasty’s board of directors failed to adequately shop the Company and obtain the best possible value for Uroplasty’s shareholders before entering into an agreement with Vision-Sciences.  According to Yahoo! Finance, at least one analyst has issued a price target for Uroplasty stock at $6.00 per share.

If you own the common stock of Uroplasty and purchased your shares before December 22, 2014, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.